NASDAQ:ATAI

Atai Life Sciences - ATAI Stock Forecast, Price & News

$3.53

+0.37 (+11.71%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.16
▼
$3.55
50-Day Range: $2.63
▼
$3.53
52-Week Range: $2.60
▼
$11.92

Volume: 2.47 million shs
Average Volume: 1.15 million shs
Market Capitalization: $585.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.83

Atai Life Sciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 602.5% Upside
$24.80 Price Target
Short Interest: Healthy
3.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.94) to ($1.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

584th out of 1,043 stocks

Pharmaceutical Preparations Industry

278th out of 510 stocks

3.4

Analyst's Opinion

Consensus Rating
Atai Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.80, Atai Life Sciences has a forecasted upside of 602.5% from its current price of $3.53.
Amount of Analyst Coverage
Atai Life Sciences has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.89% of the float of Atai Life Sciences has been sold short.
Short Interest Ratio / Days to Cover
Atai Life Sciences has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Atai Life Sciences has recently decreased by 13.16%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Atai Life Sciences does not currently pay a dividend.
Dividend Growth
Atai Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATAI.

3.2

News and Social Media Coverage

News Sentiment
Atai Life Sciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Atai Life Sciences this week, compared to 2 articles on an average week.
Search Interest
26 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 189% compared to the previous 30 days.
MarketBeat Follows
19 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 280% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atai Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.80% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.31% of the stock of Atai Life Sciences is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Atai Life Sciences are expected to decrease in the coming year, from ($0.94) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atai Life Sciences is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atai Life Sciences is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atai Life Sciences has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Atai Life Sciences (NASDAQ:ATAI) Stock

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ATAI Stock News Headlines

November 29, 2022 | finance.yahoo.com

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

November 25, 2022 | msn.com

Psychedelic Stock Gainers And Losers From November 25, 2022

November 21, 2022 | msn.com

Psychedelic Stock Gainers And Losers From November 21, 2022

November 18, 2022 | msn.com

Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today

November 17, 2022 | marketwatch.com

ADRs End Mostly Higher, Alibaba and atai Life Sciences Trade Actively

November 17, 2022 | finance.yahoo.com

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

November 11, 2022 | seekingalpha.com

Atai Life Sciences N.V. (ATAI) Q3 2022 Earnings Call Transcript

November 10, 2022 | benzinga.com

Atai Life Sciences' Q3 2022 Financials & Business Update, 'Strong Capability To Execute'

November 10, 2022 | finance.yahoo.com

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

November 8, 2022 | msn.com

Psychedelic Stock Gainers And Losers From November 8, 2022

November 4, 2022 | markets.businessinsider.com

EXCLUSIVE: Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable'

November 4, 2022 | finance.yahoo.com

Women in Psychedelics Announces atai as Platinum Sponsors

November 3, 2022 | nasdaq.com

ATAI Life Sciences N.V. Common Shares (ATAI)

November 1, 2022 | msn.com

Why Shares of atai Life Sciences Climbed 14.58% on Tuesday

November 1, 2022 | finance.yahoo.com

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

November 1, 2022 | seekingalpha.com

Atai Life Sciences a buy at Loop Capital on psychedelic wave for mental health treatments

November 1, 2022 | finance.yahoo.com

atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update

October 26, 2022 | seekingalpha.com

Compass Pathways: De-Risked (But Still Risky) Psychedelics Play Enters Phase 3

October 26, 2022 | msn.com

Psychedelic Stock Gainers And Losers From October 26, 2022

October 25, 2022 | marketwatch.com

ADRs End Mostly Higher, AstraZeneca and atai Life Sciences Trade Actively

October 25, 2022 | finance.yahoo.com

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

October 20, 2022 | finance.yahoo.com

atai Life Sciences Announces R&D Day Agenda

October 17, 2022 | msn.com

Psychedelic Stock Gainers And Losers From October 17, 2022

October 12, 2022 | msn.com

Psychedelic Stock Gainers And Losers From October 12, 2022

October 12, 2022 | nasdaq.com

Atai Says Early-stage Study Results Positive For Its KUR-101 For Treating Opioid Use Disorder

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ATAI Company Calendar

Last Earnings: 11/15/2021
Today: 12/01/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/29/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ATAI
CUSIP: N/A
CIK: 1420529
Web: www.atai.net.cn
Phone: 617-699-5876
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.80
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +603.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-167,810,000.00
Net Margins: N/A
Pretax Margin: -34,066.04%
Return on Equity: -57.87%
Return on Assets: -52.71%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 12.25
Quick Ratio: 12.25

Sales & Book Value

Annual Sales: $20.38 million
Price / Sales: 28.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.78 per share
Price / Book: 1.98

Miscellaneous

Outstanding Shares: 165,880,000
Free Float: 123,079,000
Market Cap: $585.56 million
Optionable: Not Optionable
Beta: 0.51

Key Executives

Mr. Christian Angermayer (Age 44)
Founder & Chairman of the Supervisory Board
Comp: $37.53k

Mr. Florian Brand (Age 35)
Co-founder & CEO
Comp: $627.77k

Dr. Srinivas G. Rao M.D. (Age 53)
Ph.D., Co-Founder & Chief Scientific Officer
Comp: $693.46k

Dr. Rolando Gutierrez-Esteinou M.D. (Age 61)
Chief Medical Officer
Comp: $615.38k

Mr. Gregory L. Weaver CPA (Age 66)
M.B.A., Non-Employee Advisor

Mr. Stephen B. Bardin (Age 32)
MD & CFO

Ms. Anne Johnson
Chief Accounting Officer

Ms. Madison Crawford
Sr. Mang. of Accounting

Mr. Aaqil Anwar
Mang. of Corp. Fin. & Investor Relations

Mr. Ryan Barrett
Sr. VP, Gen. Counsel & Company Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATAI Stock - Frequently Asked Questions

Should I buy or sell Atai Life Sciences stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATAI shares.
View ATAI analyst ratings or view top-rated stocks.
What is Atai Life Sciences' stock price forecast for 2023?: 4 Wall Street research analysts have issued 1-year price objectives for Atai Life Sciences' shares. Their ATAI share price forecasts range from $9.00 to $50.00. On average, they anticipate the company's stock price to reach $24.80 in the next year. This suggests a possible upside of 602.5% from the stock's current price.
View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts.
How have ATAI shares performed in 2022?: Atai Life Sciences' stock was trading at $7.63 on January 1st, 2022. Since then, ATAI shares have decreased by 53.7% and is now trading at $3.53.
View the best growth stocks for 2022 here.
When is Atai Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our ATAI earnings forecast.
How were Atai Life Sciences' earnings last quarter?: Atai Life Sciences (NASDAQ:ATAI) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. The firm earned $0.27 million during the quarter.
What other stocks do shareholders of Atai Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO).

When did Atai Life Sciences IPO?: (ATAI) raised $200 million in an IPO on Friday, June 18th 2021. The company issued 14,300,000 shares at $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg served as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.
What is Atai Life Sciences' stock symbol?: Atai Life Sciences trades on the NASDAQ under the ticker symbol "ATAI."
Who are Atai Life Sciences' major shareholders?: Atai Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (3.70%), BlackRock Inc. (0.93%), Two Sigma Investments LP (0.45%), Vanguard Group Inc. (0.29%), Credit Suisse AG (0.20%) and Two Sigma Advisers LP (0.15%). Insiders that own company stock include Apeiron Investment Group Ltd, Christian Angermayer, Gregory L Weaver and Srinivas Rao.
View institutional ownership trends.
How do I buy shares of Atai Life Sciences?: Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Atai Life Sciences' stock price today?: One share of ATAI stock can currently be purchased for approximately $3.53.
How much money does Atai Life Sciences make?: Atai Life Sciences (NASDAQ:ATAI) has a market capitalization of $585.54 million and generates $20.38 million in revenue each year. The company earns $-167,810,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.
How can I contact Atai Life Sciences?: Atai Life Sciences' mailing address is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. The official website for the company is www.atai.net.cn. The company can be reached via phone at 617-699-5876 or via email at amytung@atai.net.cn.

This page (NASDAQ:ATAI) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial